A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Arterial hypertension without previous regular treatment

• Urinary albumin excretion rate above 30 mg / 24h

• 30-65 years old

Exclusion Criteria:

• Reno-vascular arterial hypertension

• Therapy resistant edema

• Chronic heart failure, angina pectoris

• Diabetes mellitus

Other protocol-defined exclusion criteria may apply